Cogent Biosciences (COGT) Free Cash Flow (2017 - 2026)

Cogent Biosciences' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$87.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 30.23% year-over-year to -$87.3 million; the TTM figure through Mar 2026 stood at -$286.3 million (down 28.48% YoY), while the FY2025 annual figure was -$266.0 million, down 27.66% from the prior year.
• Free Cash Flow was -$87.3 million for Q1 2026 at Cogent Biosciences, down from -$79.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$27.6 million in Q2 2022 to a low of -$87.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$49.6 million across 5 years, with a median of -$44.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow tumbled 153.17% in 2022, then slipped 0.9% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$31.4 million in 2022, then slumped by 41.47% to -$44.4 million in 2023, then plunged by 36.65% to -$60.7 million in 2024, then tumbled by 31.76% to -$79.9 million in 2025, then decreased by 9.28% to -$87.3 million in 2026.
• The last three Free Cash Flow figures came in at -$87.3 million (Q1 2026), -$79.9 million (Q4 2025), and -$64.4 million (Q3 2025), per Business Quant data.